Tanezumab trial used low back pain intensity score as a primary end point and had the Roland morris index as a secondary, tanezumab seems to have made it much simpler for themselves and did not give themselves a target reduction in pain, it simply states “reduction from baseline” why have we gone for a massive 50% reduction then?
Tanezumab trial used low back pain intensity score as a primary...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.5¢ | $2.581M | 2.591M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 47648 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 128970 | 14 |
View Market Depth
| Last trade - 13.12pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |